I hold this company but I'm a little confused at this quarterly and the overall strategy of how they intend to raise the "frankly embarrassing" share price from 50c to achieve their performance rights at $1.
Looking back at announcements this years, after the rats knees fiasco, the "Internal developed products" were shelved and from the announcement "Exopharm Shareholder Update: Revenue Focus in 2021" dated 8th April 2021 we can see the main focus of revenue for 2021 was as per the below. Note the highlighted is the 4th listed bullet point, mentioned almost an an afterthought.
Then the quarterly released on 27 July 2021, developing their own medicines was apparently not even worthy of mention.
Now in October 2021 apparently the company are back to developing their own products which is a "core" focus.
I don't doubt the long term potential of exopharm and exsomes in general, however I do feel this company need to clearly identify their focus and not chop and change from quarter to quarter.
